Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jun 6;109(11):3615–3630. doi: 10.3324/haematol.2023.284332

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2024 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 3. — The number of neoepitopes is lower in Epstein-Barr virus-positive non-Hodgkin lymphoma than in Epstein-Barr virus-negative cases. (A) Number of predicted neoepitopes (log10) from the non-Ig variants within the 31 RNA samples, according to Epstein-Barr virus (EBV) status on the left and immune status (in EBV^– non-Hodgkin lymphoma) on the right. Wilcoxon test. (B) Number of predicted neoepitopes (log10) from the non-Ig variants within the 66 whole-exome sequencing samples (2 samples were excluded because of absence of germline assessment) according to EBV status. Wilcoxon test. (C) Correlation study between the number of predicted neoepitopes from the RNA and the whole-exome sequencing data (top) and between the number of predicted neoepitopes from the RNA data and the tumor mutational burden (bottom). Spearman correlation. (D) Number of predicted neoepitopes (log10) from Ig variants within the 24 RNA samples (7 samples were excluded because of dominant IgH clone <15%). Wilcoxon test. NHL: non-Hodgkin lymphoma; ID: immunodeficient; IC: immunocompetent; HIV: human immunodeficiency virus; WES: whole-exome sequencing.